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Since 1987, more than 25,000 individuals have been
immunized with 65 HIV preventive vaccines. Current can-
didate HIV-1 vaccines are complex products containing
multiple HIV genes or proteins. As a result, high propor-
tion of vaccinees score positive in licensed HIV diagnostic
kits. This will have negative impact on vaccine trials that
require early detection of breakthrough infections. For
vaccinees it may contribute to range of social harms (jobs,
insurance, blood donors). Therefore, it is important to
design new tests that will discriminate between vaccine
induced reactivity and true HIV infection. Our goals were
to identify new HIV epitopes that: 1) Do not contain
important neutralizing or CTL epitopes, 2) Recognized by
antibodies early after HIV infection. 3) Highly conserved
among HIV clades. Using Phage Display libraries con-
structed from whole HIV-1 genomes, combined with
affinity selection with antibodies from early seroconver-
tors, we identified new immunodominant epitopes, in
gp41 cytoplasmic tail and in p6 that fit the above criteria.
These peptides were used for development of new differ-
ential HIV-1 ELISA. To date, 100% specificity for gp41 and
99.4% with p6 peptide was observed with 1300 HIV
seronegative samples. Analysis of 28 early HIV serocon-
version panels showed that HIV-1 infection can be
detected within 2 weeks following HIV-1 RNA detection
by PCR. Testing of diverse HIV-1 clade panels from
around the world (1660 samples) supports the utilization
of our assay in detection of HIV-1 clade A, B, C, D, E, F and
CRF infections. The assay sensitivity is 99.1%.
In recent testing of 2780 samples obtained from six HIV
vaccine trials (with complex vaccine candidates (con-
ducted by HVTN, DOD, Vaxgen & Vaccine Research
Center), all samples from uninfected vaccines scored neg-
ative in our assay, while 46% samples were positive by
commercial diagnostic kits. Importantly, our assay
detected all 183 breakthrough HIV infections among
these vaccinees, providing a strong proof-of-concept for
utility of our EIA in diagnosis of true HIV infections in the
face of vaccine generated antibodies.
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